Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000642929 | SCV000764616 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J | 2017-11-17 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000769871 | SCV000901297 | uncertain significance | Cardiomyopathy | 2017-03-22 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002369695 | SCV002668207 | uncertain significance | Cardiovascular phenotype | 2020-02-21 | criteria provided, single submitter | clinical testing | The p.V23077I variant (also known as c.69229G>A), located in coding exon 174 of the TTN gene, results from a G to A substitution at nucleotide position 69229. The valine at codon 23077 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Fulgent Genetics, |
RCV002483833 | SCV002779849 | uncertain significance | Dilated cardiomyopathy 1G; Autosomal recessive limb-girdle muscular dystrophy type 2J; Tibial muscular dystrophy; Myopathy, myofibrillar, 9, with early respiratory failure; Early-onset myopathy with fatal cardiomyopathy; Hypertrophic cardiomyopathy 9 | 2021-08-09 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003488756 | SCV004237429 | uncertain significance | not provided | 2023-05-24 | criteria provided, single submitter | clinical testing |